At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 712 enrolled
Drug / intervention
teriparatide +3 moredrug
Likely dose
risedronate 35 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Teriparatide Compared With Risedronate on Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures
In Brief
A Phase 3 clinical trial evaluating teriparatide, risedronate, and 1 other intervention for Osteoporosis, Postmenopausal and 2 related conditions. Completed, enrolled 712 participants across 72 sites in 13 countries.
Detailed Summary
The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Postmenopausal, Back Pain, Spinal Fracture
CountriesArgentina, Australia, Belgium, Brazil, Canada, France, Germany, Italy, Mexico, Puerto Rico, Spain, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionJun 2009
Study CompletionJun 2010
TodayJul 2026
First PostedJun 22, 2006
Enrollment StartJun 1, 2006
Primary CompletionJun 1, 2009
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.0 years ago
Interventions
teriparatidedrug
20 ug/day, subcutaneous, 18 months
risedronatedrug
35 mg/once weekly, oral, 18 months
placebodrug
once weekly, oral, 18 months
placebodrug
daily, subcutaneous, 18 months